Hyperuricemia With Diabetes Compounds ESKD, Death Risks
A study conducted in Taiwan is the first to show that hyperuricemia is as risky as diabetes in contributing to ESKD and death risk in patients with stage 3 to 5 CKD.
Diabetic Nephropathy
Combining Dapagliflozin and Eplerenone Further Reduces Albuminuria in CKD
Study findings suggest the nephroprotective effects of both drug classes are complementary.
Underuse of Diabetic Kidney Disease Therapies Reported
Study findings highlight an “unmet need” for newer therapies.
Uremic Solutes Tied With Cardiovascular Death in Diabetic Kidney Disease
Investigators focused on the prognostic value of the uremic solutes asymmetric dimethylarginine, symmetric dimethylarginine, and trimethylamine-N-oxide.
Genetic Analysis Suggests BMI, Kidney Disease Link in T2DM
Mendelian randomization study shows causal association between higher body mass index and increased risk for diabetic nephropathy
Diabetes Linked With Major Bleeding Complications After Renal Biopsy
Diabetes is a possible risk factor for major bleeding complications after percutaneous renal biopsy, according to investigators.
SGLT2 Inhibitors Underprescribed for Chronic Kidney Disease
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
Atrasentan Renoprotective Across Albuminuria, Kidney Function Subgroups
Atrasentan lowers the risk for a composite of kidney failure, doubling of serum creatinine, or kidney death consistently across subgroups of urinary albumin-creatinine ratio and estimated glomerular filtration rate.
SGLT2 Inhibitors Appear Protective in CKD, Kidney Transplantation
SGLT2 inhibitors are associated with an initial dip in eGFR, so nephrologists need to monitor kidney function.
Obesity in Glomerulonephritis May Increase Risk for ESKD
Obesity rates in glomerular disease have multiplied more than 10-fold over the last 40 years.
- Loading...
Loading...
Next post in Kidney Week 2021
Loading... 
Loading...